Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Payables (2016 - 2025)

Cumberland Pharmaceuticals' Payables history spans 16 years, with the latest figure at $18.6 million for Q4 2025.

  • For Q4 2025, Payables rose 33.44% year-over-year to $18.6 million; the TTM value through Dec 2025 reached $18.6 million, up 33.44%, while the annual FY2025 figure was $18.6 million, 33.44% up from the prior year.
  • Payables for Q4 2025 was $18.6 million at Cumberland Pharmaceuticals, up from $13.8 million in the prior quarter.
  • Across five years, Payables topped out at $18.6 million in Q4 2025 and bottomed at $9.0 million in Q2 2021.
  • The 5-year median for Payables is $11.4 million (2022), against an average of $11.9 million.
  • The largest annual shift saw Payables decreased 28.03% in 2021 before it surged 33.44% in 2025.
  • A 5-year view of Payables shows it stood at $9.6 million in 2021, then increased by 12.22% to $10.8 million in 2022, then decreased by 0.01% to $10.8 million in 2023, then grew by 28.62% to $13.9 million in 2024, then soared by 33.44% to $18.6 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Payables are $18.6 million (Q4 2025), $13.8 million (Q3 2025), and $13.4 million (Q2 2025).